Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Successful completion of the 24-week study period in Study Q2143g
Signed informed consent (in the case of a minor, consent must be given by the child's parent or legally authorized representative)
For subjects who have never received Xolair, a serum IgE level \>=30 IU/mL and \<=1300 IU/mL and have a body weight \>=20 kg and \<=150 kg
Females of childbearing potential must, in the opinion of the investigator, be using an effective method of contraception to prevent pregnancy and agree to continue to practice an acceptable method of contraception for the duration of their participation in the study.
You may not be if
Thrombocytopenia as evidenced by a platelet count of \<100,000/uL
Pregnant or breastfeeding
Significant systemic disease (e.g., infection, hematologic, renal, hepatic, coronary heart disease or other cardiovascular diseases, endocrine or gastrointestinal disease) within the previous 3 months
History of neoplasia
Any systemic condition requiring regular administration of an immunoglobulin
Known hypersensitivity to any ingredients of Xolair, including excipients (sucrose, histidine, polysorbate 20)
History of noncompliance with medical regimens
Current participation in a study using an investigational new drug other than Xolair
Participation in Study Q2195g
Clareo Health | An Extension Study of Xolair in Moderate to Severe, Persistent Asthma Patients Who Completed Study Q2143g
